Annual reports filed by certain Canadian issuers pursuant to Section 15(d) and Rule 15d-4

Supplementary cash flow information (Tables)

v3.19.1
Supplementary cash flow information (Tables)
12 Months Ended
Dec. 31, 2018
Supplementary Cash Flow Information [Abstract]  
Disclosure of change in other assets and liabilities
Net change in other operating assets and liabilities

2018
$

 
2017
$

Accounts receivable and accrued interest receivable
(108
)
 
(23
)
Prepaid expenses, deposits and other
(5,094
)
 
2

Clinical trial contract deposits
90

 
(448
)
Accounts payable and accrued liabilities
(888
)
 
2,168


(6,000
)
 
1,699

Interest received
2,148

 
973

Disclosure of change in financing and investing activities
Cash flows from financing and investing activities:
 
Short term investments

 
Contingent consideration

 
Derivative warrants December 28, 2016

 
Derivative warrants February 14, 2014

 
Common shares

 
Warrants

 
Contributed surplus

Balance at
January 1, 2018
7,833

 
(3,792
)
 
(8,948
)
 
(2,845
)
 
(499,200
)
 
(906
)
 
(18,360
)
Cash flow - Purchases
36,084

 

 

 

 

 

 

Cash flow - Proceeds from short term investment
(36,093
)
 

 

 

 

 

 

Cash flow - Proceeds from exercise of warrants

 

 

 

 
(3,071
)
 

 

Cash flow - Proceeds from exercise of options

 

 

 

 
(943
)
 

 

Non-cash changes - Conversion to common shares

 

 

 

 
(1,436
)
 
906

 
530

Non-cash changes - Fair value adjustments

 
(236
)
 
(6,527
)
 
(3,427
)
 

 

 

Non-cash changes - Stock based compensation

 

 

 

 

 

 
(6,860
)
Non-cash changes - Opening adjustment on change in accounting policy
78

 

 

 

 

 

 

Non-cash changes - Other
(13
)
 

 

 

 

 

 

Balance at
December 31, 2018
7,889

 
(4,028
)
 
(15,475
)
 
(6,272
)
 
(504,650
)
 

 
(24,690
)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Balance at
January 1, 2017

 
(5,440
)
 
(7,405
)
 
(1,733
)
 
(299,815
)
 
(971
)
 
(17,017
)
Cash flow - Purchases
97,996

 

 

 

 

 

 

Cash flow - Disposals
(90,018
)
 

 

 

 

 

 

Cash flow - Payments made

 
2,150

 

 

 

 

 

Cash flow - Net proceeds from public offering

 

 

 

 
(162,324
)
 

 

Cash flow - Proceeds from exercise derivative warrants

 

 
8,596

 
88

 
(8,684
)
 

 

Cash flow - Proceeds from exercise warrants

 

 

 

 
(232
)
 

 

Cash flow - Proceeds from exercise options

 

 

 

 
(3,912
)
 

 

Non-cash changes - Conversion to Common Shares

 

 
3,825

 
8,760

 
(21,334
)
 
65

 
2,899

Non-cash changes - Fair value adjustments
(78
)
 
(502
)
 
(17,808
)
 
(10,973
)
 
(2,899
)
 

 

Non-cash changes - Stock Based Compensation

 

 

 

 

 

 
(4,242
)
Non-cash changes - Other
(67
)
 

 
3,844

 
1,013

 

 

 

Balance at
December 31, 2017
7,833

 
(3,792
)
 
(8,948
)
 
(2,845
)
 
(499,200
)
 
(906
)
 
(18,360
)